首頁 > 市場調查報告書 > 製藥

癌症分子標靶治療學

市場調查報告書

商品編碼

2104492

全球 CD70標靶治療：臨床創新、市場趨勢、治療方法、技術平台和臨床試驗洞察（2026 年）

Global CD70 Targeting Therapies Clinical Innovation, Market Trends, Therapeutic Approaches, Technology Platforms & Clinical Trials Insight 2026

出版日期: 2026年08月01日 | 出版商:

KuicK Research | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

「全球 CD70標靶治療—臨床創新、市場趨勢、治療方法、技術平台和臨床試驗洞察（2026 年）」報告的主要發現和亮點：

首個標靶治療預計將於 2032 年獲得批准。
目前，該項目處於第二階段。
CD70標靶治療臨床試驗的最新進展：超過30種治療方法
依公司、國家、適應症和研發階段深入了解 CD70標靶治療的臨床試驗。
對 FDA 和 EMA 認定進行評估，包括孤兒藥、快速通道和 RMAT。
公司對CD70技術開發平台的分析
競爭格局

CD70標靶治療的必要性及本報告的意義

CD70標靶療法已成為精準腫瘤學和下一代免疫療法領域最有前景的研究方向之一。 CD70屬於腫瘤壞死因子（TNF）配體超家族，在血液系統惡性腫瘤和某些固體癌中表達，而在正常健康組織中表達量極低。 CD70的這種生物學特異性使其成為抗癌藥物研發的理想標靶，為設計高選擇性藥物提供了機會。傳統化療會同時影響惡性細胞和快速增殖的正常細胞，而CD70標靶療法旨在特異性靶向癌細胞，從而提高療效並最大限度地降低全身毒性。目前，CD70已成為多種新型治療方法的基礎，包括單株抗體、抗體藥物複合體物（ADC）、雙特異性抗體、CAR-T細胞療法、CAR-NK細胞療法和其他免疫療法。人們對CD70的科學興趣正在迅速成長，該蛋白的應用範圍也正從腫瘤學到自體免疫疾病和發炎等領域不斷擴展。

本報告對全球CD70標靶治療市場進行了全面分析，涵蓋科學進展、臨床研究進展、所採用的技術、監管趨勢、競爭格局、區域趨勢以及未來商業性機會。本報告面向製藥公司、生技公司、投資者、研究人員以及所有對瞬息萬變的免疫療法市場感興趣的人士。本報告並非僅分析正在研發或已已通過核准的藥物，而是深入探討所有塑造CD70標靶治療未來的創新技術。

本報告包含了對CD70標靶治療臨床試驗的深入分析。

目前，包括研究、臨床前試驗、I期、I/II期和II期試驗在內的多項臨床實驗正在不同階段進行，這反映了業界對CD70治療潛力的殷切期望。本報告概述了正在開發中的臨床研發管線項目，涵蓋急性骨髓性白血病（AML）、淋巴瘤、腎細胞癌（RCC）、婦科腫瘤、肺癌、自體免疫疾病、發炎性疾病以及其他CD70陽性惡性腫瘤等關鍵適應症。報告涵蓋了單株抗體、雙特異性抗體、抗體藥物複合體（ADC）、CAR-T療法和CAR-NK療法等療法，使讀者能夠了解該研發管線的成熟度。聯合治療（包括免疫療法、表觀遺傳抑制劑、化療、標靶治療和其他創新療法）的日益普及，進一步凸顯了CD70標靶治療在臨床應用方面的巨大潛力。

積極從事CD70標靶治療研發的領導企業

近年來，CD70標靶藥物的研發競爭格局日益激烈，不僅吸引了傳統製藥公司的關注，也吸引了生物技術領域的新興參與企業。目前，眾多機構正利用各種技術平台與作用機制，開發獨特的CD70標靶療法。這些機構包括Allogene Therapeutics、OncoVerity、Ambrx（強生）、Molecular Partners和CRISPR Therapeutics，它們都透過創新舉措和臨床開發策略，不斷拓展其強大的全球產品線。除了產業相關人員之外，一些知名的教育機構和癌症研究機構也在科學檢驗和轉化研究中發揮關鍵作用，從而提升了CD70標靶療法的長期商業前景。

技術平台、合作夥伴關係和協議

技術平台創新正逐漸成為CD70療法市場的關鍵特徵之一。用於CD70療法開發的技術平台包括專有抗體工程技術、同種異體細胞生產技術、 Delta細胞平台、DARPin技術和Potelligent抗體工程技術。此外，生物技術公司、製藥公司和研究機構之間的策略合作在推動產品開發方面發揮著至關重要的作用，這種合作體現了藥物發現、生產和臨床開發方面的專業知識融合。這些合作不僅增強了產品平臺，也為產品授權協議和共同開發鋪平了道路。

一份概述 CD70標靶治療未來方向的報告。

CD70標靶治療的未來發展方向包括科學創新和拓展治療應用。聯合治療、免疫療法、多特異性抗體和新型抗體藥物複合體（ADC）等新興策略正在研發中，它們不僅有望提高療效，還能解決當前癌症治療中出現的抗藥性機制。生物標記的應用和精準醫學的進步可以進一步最佳化患者預後，並使更多患者能夠獲得CD70標靶治療。

隨著更多實驗性產品進入臨床試驗和法規核准流程，其商業化潛力將進一步提升。美國、中國和歐洲等大型市場預計將迎來更多活躍度和支持，這將有助於塑造未來的競爭格局。本報告旨在透過深入分析這些趨勢，幫助讀者掌握未來機遇，評估自身競爭地位，並了解快速變化的CD70標靶治療市場下一階段的創新發展方向。

First CD70 Targeted Therapy Approval Anticipated By 2032
Current Highest Phase Of Development: Phase-II
Insight On CD70 Targeting Therapies In Clinical Trials: > 30 Therapies
CD70 Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase
Assessment of FDA and EMA Designations, Including Orphan Drug, Fast Track & RMAT
Company Wise Analysis Of CD70 Technology Development Platforms
Competitive Landscape

Need For CD70 Targeted Therapies & Why This Report?

Targeted therapies against CD70 have turned out to be one of the most promising areas of precision oncology and next generation immunotherapy. CD70 belongs to the tumor necrosis factor (TNF) ligand superfamily that is expressed in hematological and selected solid malignancies while being expressed only weakly in normal healthy tissues. Such biological specificity of CD70 makes it an excellent target for cancer therapy development as it provides an opportunity to design highly selective drugs. While traditional chemotherapy influences both malignant and healthy rapidly dividing cells, CD70 targeted therapy is intended to specifically target tumor cells, which can increase efficacy and minimize systemic toxicity. In present days CD70 acts as a basis of several novel therapeutic approaches such as monoclonal antibodies, ADCs, bispecific antibodies, CAR-T cell therapy, CAR-NK cell therapy and other immune cell therapy. The scientific interest in CD70 is rapidly gaining momentum with the widening scope of applications for this protein from oncology to autoimmune diseases and inflammation.

This report presents an extensive analysis of the worldwide market for CD70 targeted therapy that incorporates scientific developments, advances in clinical research, technologies used, regulatory developments, competitive intelligence, geographical trends, and commercial opportunities for the future. This report is intended for pharmaceutical, biotech companies, investors, researchers, and others who are interested in the highly dynamic immunotherapy market. Instead of analyzing only advanced and approved drugs, this report considers all innovations that define the future of CD70 targeted therapy.

CD70 Targeted Therapy Clinical Trials Insight Included In Report

A number of investigative treatments are now underway at various levels of research, preclinical, Phase I, Phase I/II, and Phase II investigations, underscoring the high level of industry confidence in the therapeutic potential of CD70. The report reviews clinical pipeline programs being developed in important disease indications like acute myeloid leukemia (AML), lymphoma, renal cell carcinoma (RCC), gynecological cancers, lung cancer, autoimmune conditions, inflammatory conditions, and other CD70 positive malignancies. Monoclonal antibodies, bispecific antibodies, antibody drug conjugates, CAR-T therapies, and CAR NK therapies are some of the therapies that are reviewed here, enabling the reader to understand the maturity of the pipeline. Increased focus on combination treatments comprising immunotherapy, epigenetic inhibitors, chemotherapy, targeted therapy, and other innovations serves to further highlight the growing potential in clinical applications of CD70 targeted therapies.

Major Companies Active In R&D Of CD70 Targeted Therapies

In recent years, the competitive environment associated with CD70 targeted drug development has become highly dynamic, drawing interest not only from traditional pharma companies but also from new players in the biotech space. There are now many organizations that have distinct programs focused on CD70 using different technology platforms and modes of action. These include Allogene Therapeutics, OncoVerity, Ambrx (Johnson & Johnson), Molecular Partners, CRISPR Therapeutics, among others, have been adding to the robust global pipeline with their creative research initiatives and clinical growth strategies. Apart from the stakeholders in the industry, some prominent educational institutes and cancer research facilities are playing a key role in scientific validation and translational research, thereby enhancing the long term business prospects of the therapies targeting CD70.

Technology Platforms, Collaborations & Agreements

It is clear that innovation in technology platforms has emerged as one of the key features of the market for CD70 therapies. The technology platforms that have been employed for the development of CD70 therapies include proprietary antibody engineering technologies, allogeneic manufacturing technologies, gamma delta cell platforms, DARPin technologies, Potelligent antibody engineering, etc. Additionally, strategic alliances among biotechnology companies, pharmaceutical companies and research institutes are playing a crucial role in promoting product development through collaboration of skills in drug discovery, manufacturing and clinical development of products. These alliances will not only enhance the product pipeline but also pave the way for licensing agreements and co-development of products.

Report Indicating Future Direction Of CD70 Targeted Therapies

Future directions of CD70 targeted therapies include scientific innovation and increasing applications of the therapies. Combination therapies, immune cell therapies, multispecific antibodies, and novel antibody drug conjugates are some of the new strategies being developed that may enhance efficacy as well as address the mechanisms of resistance seen with current cancer treatments. The use of biomarkers and advancements in precision medicine could lead to an enhanced optimization of patient treatment results and increased usage of the CD70 targeting therapy.

More commercialization potential will be realized as more experimental products enter into the stage of clinical trials and regulatory approval process. There will be more activity and support in large markets like the US, China, and Europe, which will help build the competition in the future. The report offers an outlook on these developments, thus providing readers the ability to recognize future opportunities, assess competitive positioning, and understand the next stage of innovation in the fast changing CD70 targeting therapies market.

1. Research Methodology

2. Introduction To CD70 Targeting Therapy

2.1 CD70 Targeting Therapy Overview
2.2 Dual Role of CD70 As Diagnostic & Prognostic Biomarker

3. CD70 Targeting Therapeutic Approaches

3.1 Monoclonal Antibody
3.2 Bispecific Antibody
3.3 Tetraspecific Antibody
3.4 CAR T Cell Therapy
3.5 Antibody Drug Conjugate
3.6 CAR-NK Therapy

4. CD70 Targeting Therapies Technology Development Platforms By Company

5. Global CD70 Targeting Therapies Current Market Trend & Developments

5.1 Current Market Outline
5.2 Future Market Forecast
5.3 Regulatory Designations: Fast Track & Orphan Designation

6. CD70 Targeting Therapies Market Opportunity & Clinical Trends By Region

6.1 US
6.2 China
6.3 Europe

7. CD70 Targeting Therapies Clinical Research & Innovation By Indications

7.1 Leukemia
7.2 Lymphoma
7.3 Gynecologic Cancer
7.4 Renal Cell Carcinoma
7.5 Lung Cancer
7.6 Autoimmune & Inflammatory Disease
7.7 Viral Infections

8. Global CD70 Targeting Therapies Clinical Trials Overview

8.1 By Phase
8.2 By Country
8.3 By Company
8.4 By Indication
8.5 By Priority Status

9. Global CD70 Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase

9.1 Research
9.2 Preclinical
9.3 Phase I
9.4 Phase I/II
9.5 Phase II

10. Combination Strategies For CD70 Targeting Therapies

10.1 In Combination With Immunotherapy
10.2 In Combination With Epigenetic Modulators
10.3 In Combination With Targeted Therapy
10.4 In Combination With Oncolytic Virus Therapy
10.5 In Combination With Chemotherapy

11. Global CD70 Targeting Therapies Market Dynamics

11.1 Market Drivers
11.2 Market Challenges

12. Competitive Landscape

12.1 Adaptimmune
12.2 Allogene Therapeutics
12.3 Ambrx (Johnson & Johnson)
12.4 Chongqing Precision Biotech
12.5 CRISPR Therapeutics
12.6 ImmuneOnco Biopharma
12.7 Molecular Partners
12.8 Pfizer
12.9 Poseida Therapeutics
12.10 Shenzhen Geno-Immune Medical Institute

簡介目錄圖表

List of Figures

Figure 2-1: Introduction To CD70 Protein
Figure 2-2: History & Development Of CD70 Targeting Therapies
Figure 2-3: CD70 As Diagnostic & Prognostic Marker In Cancer
Figure 3-1: Approaches For Targeting CD70
Figure 4-1: Allogene Therapeutics - AlloCAR T Platform
Figure 4-2: Adicet Bio - Gamma Delta Cell Platform
Figure 4-3: ADI-270 - CD70 CAR Yδ T Cell Therapy
Figure 4-4: Catamaran Bio - Tailwind Platform
Figure 4-5: Molecular Partners - DARPin Platform
Figure 4-6: Nkarta - CAR-NK Cells
Figure 4-7: Nkarta - Proprietary CAR-NK Cells Manufacturing Process
Figure 5-1: CD70 Targeting Therapy Current Market - Guiding Factors
Figure 5-2: Key Players In CD70 Market
Figure 5-3: CD70 Targeting Therapy Market Future - Influencing Factors
Figure 7-1: Role Of CD70 In Leukemia
Figure 7-2: Molecular Partners - MP0533
Figure 7-3: MP0533-CP101 Phase I/II (NCT05673057) Study - Initiation & Completion Year
Figure 7-4: CULMINATE Phase II (NCT04023526) Study - Initiation & Completion Year
Figure 7-5: OV-AML-1231 Phase II (NCT06384261) Study - Initiation & Completion Year
Figure 7-6: Role Of CD70 In Leukemia
Figure 7-7: NCI-2021-12093 Phase I/II (NCT05092451) Study - Initiation & Completion Year
Figure 7-8: 2022-088 Phase I (NCT05667155) Study - Initiation & Completion Year
Figure 7-9: CD70 CAR T Therapy Early Phase I (NCT04662294) Study - Initiation & Completion Year
Figure 7-10: Lymphoma: Key Market Players Conducting CD70 Clinical Research
Figure 7-11: Role Of CD70 In Gynecologic Cancers
Figure 7-12: PBC052 CAR-T Therapy Phase I (NCT06010875) Study - Initiation & Completion Year
Figure 7-13: 16-C-0131 Phase I/II (NCT02830724) Study - Initiation & Completion Year
Figure 7-14: Role Of CD70 In Renal Cell Carcinoma
Figure 7-15: Research By Allogene Therapeutics
Figure 7-16: TRAVERSE Phase 1 (NCT04696731) Study - Initiation & Completion Year
Figure 7-17: Role Of CD70 In Lung Cancer
Figure 7-18: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 7-19: RESOLUTION Phase 1 (NCT07085104) Study - Initiation & Completion Year
Figure 7-20: PBC103 Phase 1 (NCT07184450) Study - Initiation & Completion Year
Figure 7-21: PBC088 Phase 1 (NCT06934447) Study - Initiation & Completion Year
Figure 7-22: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 8-1: Global - Number Of CD70 Targeting Therapies in Clinical Trials By Phase, 2026
Figure 8-2: Global - Number Of CD70 Targeting Therapies In Clinical Trials By Country, 2026
Figure 8-3: Global - Number Of CD70 Targeting Therapies In Clinical Trials By Company, 2026
Figure 8-4: Global - Number Of CD70 Targeting Therapies In Clinical Trials By Indication, 2026
Figure 8-5: Global - Number Of CD70 Targeting Therapies In Clinical Trials By Priority Status, 2026
Figure 10-1: Combinations Of CD70 Therapy With Other Therapies
Figure 11-1: Global CD70 Targeting Therapy Market - Drivers
Figure 11-2: Global CD70 Targeting Therapy Market - Challenges

List of Tables

Table 5-1: CD70 Targeting Therapies With Regulatory Designations

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

伊沙貝隆市場規模、佔有率和成長分析：按適應症、療法、治療階段、分銷管道、最終用戶和地區分類－2026-2033年產業預測

全球 DLL3 標靶治療市場：市場機會、已通過核准療法銷售、定價、專有開發平台和臨床試驗洞察（2030 年）

全球 Claudin 18.2 標靶治療市場機會、治療方法、已核准藥物定價、銷售及臨床試驗展望（2030 年）

CD40標靶治療藥的全球市場:臨床試驗，治療方法，專利技術平台，市場機會相關洞察(2026年)

OX40標靶治療藥的臨床試驗，治療方法，專利技術平台，市場機會(2026年)

全球 CD123 標靶治療市場：市場趨勢、臨床試驗、技術平台、未來展望 (2025)

CD5標靶治療藥的全球市場:市場趨勢，臨床試驗，技術平台，未來預測(2025年)

CD40標靶治療的全球市場:臨床試驗，治療方法，市場機會的洞察(2025年)

Claudin18.2標靶治療的全球市場:市場預測和臨床試驗趨勢(2029年)

FAQ

全球 CD70標靶治療：臨床創新、市場趨勢、治療方法、技術平台和臨床試驗洞察（2026 年）

Global CD70 Targeting Therapies Clinical Innovation, Market Trends, Therapeutic Approaches, Technology Platforms & Clinical Trials Insight 2026

目錄

第1章：調查方法

第2章：CD70標靶治療簡介

第3章：標靶CD70的治療方法

第4章：各公司CD70標靶治療技術開發平台

第5章：全球CD70標靶治療的現況及市場趨勢

第6章：CD70標靶治療的市場機會與區域臨床趨勢

第7章：CD70標靶治療適應症的臨床調查與創新

第8章：CD70標靶治療相關臨床試驗概述

第9章全球CD70標靶治療臨床試驗概覽（按公司、國家、適應症和階段分類）

第10章：CD70標靶治療的聯合療法

第11章：全球CD70標靶治療市場動態

第12章競爭格局